10 research outputs found
Adolescents’ Behaviors as Moderators for the Link between Parental Self-Efficacy and Parenting Practices
Pan-cancer analysis of whole genomes
Cancer is driven by genetic change, and the advent of massively parallel sequencing has enabled systematic documentation of this variation at the whole-genome scale(1-3). Here we report the integrative analysis of 2,658 whole-cancer genomes and their matching normal tissues across 38 tumour types from the Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium of the International Cancer Genome Consortium (ICGC) and The Cancer Genome Atlas (TCGA). We describe the generation of the PCAWG resource, facilitated by international data sharing using compute clouds. On average, cancer genomes contained 4-5 driver mutations when combining coding and non-coding genomic elements; however, in around 5% of cases no drivers were identified, suggesting that cancer driver discovery is not yet complete. Chromothripsis, in which many clustered structural variants arise in a single catastrophic event, is frequently an early event in tumour evolution; in acral melanoma, for example, these events precede most somatic point mutations and affect several cancer-associated genes simultaneously. Cancers with abnormal telomere maintenance often originate from tissues with low replicative activity and show several mechanisms of preventing telomere attrition to critical levels. Common and rare germline variants affect patterns of somatic mutation, including point mutations, structural variants and somatic retrotransposition. A collection of papers from the PCAWG Consortium describes non-coding mutations that drive cancer beyond those in the TERT promoter(4); identifies new signatures of mutational processes that cause base substitutions, small insertions and deletions and structural variation(5,6); analyses timings and patterns of tumour evolution(7); describes the diverse transcriptional consequences of somatic mutation on splicing, expression levels, fusion genes and promoter activity(8,9); and evaluates a range of more-specialized features of cancer genomes(8,10-18).Peer reviewe
Otimização de Parâmetros Operacionais do Processo de Soldagem FCAW para Aplicação em Revestimento Duro
Effect of lactoferrin- and transferrin-conjugated polymersomes in brain targeting: in vitro and in vivo evaluations
Factors Moderating the Relationship Between Childhood Trauma and Premorbid Adjustment in First-Episode Schizophrenia
Physical function and quality of life in patients with chronic graft-versus-host-disease: A summary of preclinical and clinical studies and a call for exercise intervention trials in patients
Allogeneic Hematopoietic Stem Cell Transplant, to reconstitute hematopoietic and immune status
of patients undergoing myeloablative therapy for hematologic disorders, has been of great benefit
in minimizing or eradicating disease and extending survival. Patients who undergo allogeneic
hematopoietic stem cell transplant (allo-HSCT) are subject to many comorbidities among which
the most significant, affecting quality of life (QoL) and survival, are acute (aGVHD) and chronic
Graft Versus Host Disease (cGVHD), resulting from donor lymphocytes reacting to and damaging
host tissues. Physical activity and exercise have clearly been shown, in both children and adults, to
enhance fitness, improve symptomatology and QoL, reduce disease progression and extend
survival for many diseases including malignancies. In some cases, vigorous exercise has been
shown to be equal to or more effective than pharmacologic therapy. This review addresses how
cGVHD affects patients’ physical function and physical domain of QoL, and the potential benefits
of exercise interventions along with recommendations for relevant research and evaluation targeted at incorporating this strategy as soon as possible after allo-HSCT and ideally, as soon as
possible upon diagnosis of the condition leading to allo-HSCT.Sin financiación3.874 JCR (2016) Q2, 20/70 Hematology, 48/151 Immunology, 71/217 Oncology, 7/25 Transplantation1.986 SJR (2016) Q1, 18/135 Hematology, 5/42 TransplantationNo data IDR 2016UE